Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?

Lung Cancer - Episode 1

Apr 1, 2021

Charu Aggarwal, MD, MPH, Leslye M. Heisler Associate Professor for Lung Cancer ExcellenceDevika Das, MD, Thoracic Medical OncologistH. Jack West, MD, Vice President, Clinical Development

Roy S. Herbst, MD, PhD, shares thoughts on the update to Keynote-024 presented at ESMO 2020

Roy S. Herbst, MD, PhD, elaborates on the design and outcomes of the EMPOWER-lung 1 clinical study

Roy S. Herbst, MD, PhD, tell us about the PIONeeR study presented at the 2020 ESMO Virtual Congress

Charu Aggarwal, MD, Devika Das, MD, and H. Jack West, MD, discuss their impressions of Impower010 investigating immunotherapy in early-stage non-small cell lung cancer, and whether the data appears strong enough to use immunotherapy in this setting.

© 2025 HealthCentral LLC. All rights reserved.

More Videos

2025’s Most Anticipated Advances in Lung Cancer

Eric K. Singhi, MD; Maya Khalil, MD; Sandip P. Patel, MD

Wave of FDA Approvals Marks Big Year for Lung Cancer

Maya Khalil, MD; Eric K. Singhi, MD; Sandip P. Patel, MD

HER2-Targeting in Lung Cancer: What’s Next?

Maya Khalil, MD; Sandip P. Patel, MD; Eric K. Singhi, MD

FDA Approvals in NSCLC Mean “Difficult Decisions”

Eric K. Singhi, MD; Maya Khalil, MD; Sandip P. Patel, MD

More Like This

2025’s Most Anticipated Advances in Lung Cancer

Eric K. Singhi, MD; Maya Khalil, MD; Sandip P. Patel, MD

2024 was packed with advances in lung cancer care. What will 2025 hold? The panel shares which potential breakthroughs they are most looking forward to seeing.

2025’s Most Anticipated Advances in Lung Cancer

Eric K. Singhi, MD; Maya Khalil, MD; Sandip P. Patel, MD

2024 was packed with advances in lung cancer care. What will 2025 hold? The panel shares which potential breakthroughs they are most looking forward to seeing.

Small Cell Lung Cancer (SCLC)

ASCO Updates Recommendations for SCLC

ASCO recently released a guideline rapid recommendation update for systemic therapy in patients with SCLC based on results of two key recent clinical trials.

Small Cell Lung Cancer (SCLC)

ASCO Updates Recommendations for SCLC

ASCO recently released a guideline rapid recommendation update for systemic therapy in patients with SCLC based on results of two key recent clinical trials.

Non-Small Cell Lung Cancer (NSCLC)

Treating Stage III NSLC Remains a Challenge

ASCO updated stage III NSCLC treatment guidance after the LAURA trial. But for patients without oncogenic driver mutations, optimal treatment remains unclear.

Non-Small Cell Lung Cancer (NSCLC)

Treating Stage III NSLC Remains a Challenge

ASCO updated stage III NSCLC treatment guidance after the LAURA trial. But for patients without oncogenic driver mutations, optimal treatment remains unclear.

Wave of FDA Approvals Marks Big Year for Lung Cancer

Maya Khalil, MD; Eric K. Singhi, MD; Sandip P. Patel, MD

Lung cancer treatment options greatly expanded this year. Our panel discusses 8 significant approvals by the FDA in “a year packed with lung cancer advancements.”

Wave of FDA Approvals Marks Big Year for Lung Cancer

Maya Khalil, MD; Eric K. Singhi, MD; Sandip P. Patel, MD

Lung cancer treatment options greatly expanded this year. Our panel discusses 8 significant approvals by the FDA in “a year packed with lung cancer advancements.”

Non-Small Cell Lung Cancer (NSCLC)

FDA Approves Ensartinib for Advanced NSCLC

The FDA approved ensartinib for adults with ALK-mutated locally advanced or metastatic non-small cell lung cancer who have not received prior ALK-targeted therapy.

Non-Small Cell Lung Cancer (NSCLC)

FDA Approves Ensartinib for Advanced NSCLC

The FDA approved ensartinib for adults with ALK-mutated locally advanced or metastatic non-small cell lung cancer who have not received prior ALK-targeted therapy.

Non-Small Cell Lung Cancer (NSCLC)

FDA Rejects Subcutaneous Amivantamab for NSCLC

The FDA rejected a BLA seeking approval for a subcutaneous amivantamab combination for use in EGFR-mutated non-small cell lung cancer.

Non-Small Cell Lung Cancer (NSCLC)

FDA Rejects Subcutaneous Amivantamab for NSCLC

The FDA rejected a BLA seeking approval for a subcutaneous amivantamab combination for use in EGFR-mutated non-small cell lung cancer.

Non-Small Cell Lung Cancer (NSCLC)

2024’s Biggest News in NSCLC Care

Dr. Roy Herbst shares the top news in 2024 for non-small cell lung cancer, including key research and emerging treatment strategies.

Non-Small Cell Lung Cancer (NSCLC)

2024’s Biggest News in NSCLC Care

Dr. Roy Herbst shares the top news in 2024 for non-small cell lung cancer, including key research and emerging treatment strategies.

Non-Small Cell Lung Cancer (NSCLC)

FDA Approves Bispecific in Lung, Pancreatic Cancer

The FDA granted accelerated approval to zenocutuzumab for adults with NRG1-positive NSCLC or pancreatic adenocarcinoma.

Non-Small Cell Lung Cancer (NSCLC)

FDA Approves Bispecific in Lung, Pancreatic Cancer

The FDA granted accelerated approval to zenocutuzumab for adults with NRG1-positive NSCLC or pancreatic adenocarcinoma.

Small Cell Lung Cancer (SCLC)

FDA Approves Durvalumab for Limited-Stage SCLC

The FDA approved durvalumab for adults with limited-stage small cell lung cancer who have not progressed after chemotherapy and radiation treatment.

Small Cell Lung Cancer (SCLC)

FDA Approves Durvalumab for Limited-Stage SCLC

The FDA approved durvalumab for adults with limited-stage small cell lung cancer who have not progressed after chemotherapy and radiation treatment.

Small Cell Lung Cancer (SCLC)

Big Year in SCLC: Clinical Highlights From 2024

2024 has been a big year for SCLC, with “astounding” results from a major clinical trial leading to a new standard of care among the significant developments.

Small Cell Lung Cancer (SCLC)

Big Year in SCLC: Clinical Highlights From 2024

2024 has been a big year for SCLC, with “astounding” results from a major clinical trial leading to a new standard of care among the significant developments.

Non-Small Cell Lung Cancer (NSCLC)

Pick an “Old Friend” or New FDA Approvals in NSCLC?

Kamya Sankar, MD; Robert A. Figlin, MD, FACP

Kamya Sankar, MD, and Robert A. Figlin, MD, discuss how to choose between an “old friend” in osimertinib and new options in EGFR-mutated metastatic NSCLC.

Non-Small Cell Lung Cancer (NSCLC)

Pick an “Old Friend” or New FDA Approvals in NSCLC?

Kamya Sankar, MD; Robert A. Figlin, MD, FACP

Kamya Sankar, MD, and Robert A. Figlin, MD, discuss how to choose between an “old friend” in osimertinib and new options in EGFR-mutated metastatic NSCLC.

FDA Actions & News

Oncology Drugs Fast-Tracked by FDA in October 2024

In October, the U.S. Food and Drug Administration fast-tracked several drugs in oncology. Here are highlights in lung, brain, and ovarian cancer and more.

FDA Actions & News

Oncology Drugs Fast-Tracked by FDA in October 2024

In October, the U.S. Food and Drug Administration fast-tracked several drugs in oncology. Here are highlights in lung, brain, and ovarian cancer and more.